	US 12,152,027 B2
	Heterocyclic compound
Takaharu Hirayama, Kanagawa (JP); Yoshiteru Ito, Kanagawa (JP); Noriyuki Nii, Kanagawa (JP); Youichi Kawakita, Kanagawa (JP); and Shinichi Imamura, Kanagawa (JP)
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Appl. No. 17/296,434
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
PCT Filed Nov. 27, 2019, PCT No. PCT/JP2019/046261 § 371(c)(1), (2) Date May 24, 2021, PCT Pub. No. WO2020/111087, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. 2018-222530 (JP), filed on Nov. 28, 2018.
Prior Publication US 2022/0048916 A1, Feb. 17, 2022
Int. Cl. C07D 487/04 (2006.01); C07D 471/04 (2006.01)

CPC C07D 471/04 (2013.01) [C07D 487/04 (2013.01)]

4 Claims

1. A pharmaceutical composition comprising a compound or a salt thereof, or a co-crystal, a hydrate, or a solvate thereof, wherein the compound is (S)-N-(6-chloro-4-(1-methoxyethyl)-1,5-naphthyridin-3-yl)-N′-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea.